Health and Healthcare
Is the FDA Canceling This Schizophrenia Treatment?
Published:
Last Updated:
Intra-Cellular Therapies Inc. (NASDAQ: ITCI) shares dipped on Tuesday after the firm gave an update from the U.S. Food and Drug Administration (FDA).
Essentially, the FDA informed Intra-Cellular that it does not have plans to schedule an Advisory Committee meeting in connection with its review of the company’s New Drug Application (NDA) for lumateperone for the treatment of schizophrenia. The lumateperone Prescription Drug User Fee Act (PDUFA) goal date is December 27, 2019.
Additionally, the firm recently submitted to the FDA the results of nonclinical analyses Intra-Cellular previously announced it had agreed to conduct related to toxicology findings in animal studies.
The company believes the results of these analyses provide additional support for its position that the metabolic pathway, and the metabolites formed, are different in animals and humans and therefore toxicity findings in animals are not relevant to humans.
Dr. Sharon Mates, board chair and chief executive of Intra-Cellular, commented:
We have been working diligently to address the FDA requests for information and are optimistic that the additional non-clinical information we submitted addresses those requests. There is an ongoing unmet need for new treatments for schizophrenia and we look forward to continuing our work with the FDA to bring lumateperone to patients.
Shares of Intra-Cellular traded down about 5% to $9.78 on Tuesday. The 52-week range is $7.41 to $23.62, and the consensus price target is $25.89.
24/7 Wall St.Credit Card Companies Are Doing Something Nuts
Credit card companies are at war. The biggest issuers are handing out free rewards and benefits to win the best customers.
It’s possible to find cards paying unlimited 1.5%, 2%, and even more today. That’s free money for qualified borrowers, and the type of thing that would be crazy to pass up. Those rewards can add up to thousands of dollars every year in free money, and include other benefits as well.
We’ve assembled some of the best credit cards for users today. Don’t miss these offers because they won’t be this good forever.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
